The Latest Analyst Ratings for Integra Lifesciences
Portfolio Pulse from Benzinga Insights
Integra Lifesciences (NASDAQ:IART) has received mixed analyst ratings in the last quarter, with an average 12-month price target of $43.75, ranging from $37.00 to $50.00. The average price target has risen by 4.99% over the past month. Ratings include 1 bullish, 1 somewhat bullish, 1 indifferent, and 1 somewhat bearish, with no bearish ratings. Analysts typically review stocks quarterly and provide insights based on company performance, financial statements, and insider communications.
December 05, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Integra Lifesciences has a mixed outlook from analysts, with an average price target that has increased by nearly 5% over the past month, indicating a positive sentiment shift.
The increase in the average price target suggests a positive sentiment among analysts, which could lead to a short-term positive impact on IART's stock price. However, the mixed ratings with only one bullish and one somewhat bullish rating against one indifferent and one somewhat bearish rating indicate that the outlook is not uniformly positive, which tempers the potential impact.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100